Engineered immune cells with micro-clusters

USPTO issued patent grant US12595291B2 to A2 Biotherapeutics, Inc. for engineered immune cells with micro-clusters. The patent covers immune cells comprising both activating and blocking receptors that self-assemble into micro-clusters when contacting target or non-target cells, with applications in cell-based therapies.

For A2 Biotherapeutics and competitors in the cell therapy space, this patent establishes intellectual property protection for micro-cluster formation in engineered immune cells. Parties developing similar cell engineering technologies should conduct freedom-to-operate analyses to avoid infringement. The patent holder gains exclusive rights to commercialize products embodying the claimed engineered immune cells and associated methods.